Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Buy
75
DNLI Quote, Financials, Valuation and Earnings
Last price:
$20.12
Seasonality move
:
-5.77%
Day range:
$18.47 - $20.49
52-week range:
$10.57 - $26.18
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
6.62x
P/B ratio:
3.01x
Volume:
1.5M
Avg. volume:
1.4M
1-year change:
-20.47%
Market cap:
$2.8B
Revenue:
--
EPS (TTM):
-$2.91
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
DNLI
Denali Therapeutics, Inc.
|
$1M | -$0.76 | 559.6% | -13.28% | $32.00 |
|
AGEN
Agenus, Inc.
|
$80.4M | $2.20 | 144.6% | -70.59% | $12.33 |
|
AIM
AIM ImmunoTech
|
-- | -$0.09 | -23.08% | -53.85% | $4.50 |
|
ARMP
Armata Pharmaceuticals, Inc.
|
$1.4M | -$0.42 | 19.84% | -177.23% | $9.00 |
|
NVAX
Novavax, Inc.
|
$41.6M | -$1.13 | 2.21% | -8.63% | $12.67 |
|
PLX
Protalix Biotherapeutics, Inc.
|
$17.9M | -- | -7.76% | -- | $11.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
DNLI
Denali Therapeutics, Inc.
|
$19.00 | $32.00 | $2.8B | -- | $0.00 | 0% | 6.62x |
|
AGEN
Agenus, Inc.
|
$4.17 | $12.33 | $141.8M | -- | $0.00 | 0% | 1.05x |
|
AIM
AIM ImmunoTech
|
$0.04 | $4.50 | $2.8M | -- | $0.00 | 0% | 13.27x |
|
ARMP
Armata Pharmaceuticals, Inc.
|
$5.99 | $9.00 | $217.6M | -- | $0.00 | 0% | 49.69x |
|
NVAX
Novavax, Inc.
|
$6.84 | $12.67 | $1.1B | 3.87x | $0.00 | 0% | 1.09x |
|
PLX
Protalix Biotherapeutics, Inc.
|
$1.72 | $11.00 | $138.3M | 24.75x | $0.00 | 0% | 2.19x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
DNLI
Denali Therapeutics, Inc.
|
4.58% | 1.220 | 2.09% | 9.43x |
|
AGEN
Agenus, Inc.
|
510.35% | 4.383 | 285.06% | 0.03x |
|
AIM
AIM ImmunoTech
|
48.41% | 0.745 | 17.25% | 0.71x |
|
ARMP
Armata Pharmaceuticals, Inc.
|
216.44% | 3.715 | 164.57% | 0.11x |
|
NVAX
Novavax, Inc.
|
265.85% | 2.153 | 17.83% | 1.90x |
|
PLX
Protalix Biotherapeutics, Inc.
|
13.39% | -1.718 | 4.58% | 2.00x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
DNLI
Denali Therapeutics, Inc.
|
-$2.9M | -$137.4M | -42.48% | -44.34% | -- | -$105.9M |
|
AGEN
Agenus, Inc.
|
$26.6M | -$4.9M | -39.69% | -- | -16.08% | -$14.7M |
|
AIM
AIM ImmunoTech
|
$27K | -$4.5M | -219.06% | -256.33% | -9994.29% | -$3.3M |
|
ARMP
Armata Pharmaceuticals, Inc.
|
$789K | -$7.8M | -57.86% | -- | -670.92% | -$4.5M |
|
NVAX
Novavax, Inc.
|
$50.6M | -$79.4M | -- | -- | -112.72% | $105.8M |
|
PLX
Protalix Biotherapeutics, Inc.
|
$9.5M | $2.1M | 10.63% | 12.06% | 11.94% | -$4.2M |
Denali Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns DNLI or AGEN?
Agenus, Inc. has a net margin of -- compared to Denali Therapeutics, Inc.'s net margin of -116.82%. Denali Therapeutics, Inc.'s return on equity of -44.34% beat Agenus, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital DNLIDenali Therapeutics, Inc.-- -$0.74 $970.6M AGENAgenus, Inc.87.85% $1.94 $60.1M -
What do Analysts Say About DNLI or AGEN?
Denali Therapeutics, Inc. has a consensus price target of $32.00, signalling upside risk potential of 68.42%. On the other hand Agenus, Inc. has an analysts' consensus of $12.33 which suggests that it could grow by 195.76%. Given that Agenus, Inc. has higher upside potential than Denali Therapeutics, Inc., analysts believe Agenus, Inc. is more attractive than Denali Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings DNLIDenali Therapeutics, Inc.17 0 0 AGENAgenus, Inc.2 1 0 -
Is DNLI or AGEN More Risky?
Denali Therapeutics, Inc. has a beta of 1.115, which suggesting that the stock is 11.475% more volatile than S&P 500. In comparison Agenus, Inc. has a beta of 1.510, suggesting its more volatile than the S&P 500 by 51.01%.
-
Which is a Better Dividend Stock DNLI or AGEN?
Denali Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Agenus, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Denali Therapeutics, Inc. pays -- of its earnings as a dividend. Agenus, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios DNLI or AGEN?
Denali Therapeutics, Inc. quarterly revenues are --, which are smaller than Agenus, Inc. quarterly revenues of $30.2M. Denali Therapeutics, Inc.'s net income of -$126.9M is lower than Agenus, Inc.'s net income of $63.9M. Notably, Denali Therapeutics, Inc.'s price-to-earnings ratio is -- while Agenus, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Denali Therapeutics, Inc. is 6.62x versus 1.05x for Agenus, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DNLIDenali Therapeutics, Inc.6.62x -- -- -$126.9M AGENAgenus, Inc.1.05x -- $30.2M $63.9M
-
Which has Higher Returns DNLI or AIM?
AIM ImmunoTech has a net margin of -- compared to Denali Therapeutics, Inc.'s net margin of -10571.43%. Denali Therapeutics, Inc.'s return on equity of -44.34% beat AIM ImmunoTech's return on equity of -256.33%.
Company Gross Margin Earnings Per Share Invested Capital DNLIDenali Therapeutics, Inc.-- -$0.74 $970.6M AIMAIM ImmunoTech77.14% -$0.06 $5.6M -
What do Analysts Say About DNLI or AIM?
Denali Therapeutics, Inc. has a consensus price target of $32.00, signalling upside risk potential of 68.42%. On the other hand AIM ImmunoTech has an analysts' consensus of $4.50 which suggests that it could grow by 11066.25%. Given that AIM ImmunoTech has higher upside potential than Denali Therapeutics, Inc., analysts believe AIM ImmunoTech is more attractive than Denali Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings DNLIDenali Therapeutics, Inc.17 0 0 AIMAIM ImmunoTech1 0 0 -
Is DNLI or AIM More Risky?
Denali Therapeutics, Inc. has a beta of 1.115, which suggesting that the stock is 11.475% more volatile than S&P 500. In comparison AIM ImmunoTech has a beta of 0.760, suggesting its less volatile than the S&P 500 by 23.953%.
-
Which is a Better Dividend Stock DNLI or AIM?
Denali Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. AIM ImmunoTech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Denali Therapeutics, Inc. pays -- of its earnings as a dividend. AIM ImmunoTech pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios DNLI or AIM?
Denali Therapeutics, Inc. quarterly revenues are --, which are smaller than AIM ImmunoTech quarterly revenues of $35K. Denali Therapeutics, Inc.'s net income of -$126.9M is lower than AIM ImmunoTech's net income of -$3.7M. Notably, Denali Therapeutics, Inc.'s price-to-earnings ratio is -- while AIM ImmunoTech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Denali Therapeutics, Inc. is 6.62x versus 13.27x for AIM ImmunoTech. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DNLIDenali Therapeutics, Inc.6.62x -- -- -$126.9M AIMAIM ImmunoTech13.27x -- $35K -$3.7M
-
Which has Higher Returns DNLI or ARMP?
Armata Pharmaceuticals, Inc. has a net margin of -- compared to Denali Therapeutics, Inc.'s net margin of -2301.55%. Denali Therapeutics, Inc.'s return on equity of -44.34% beat Armata Pharmaceuticals, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital DNLIDenali Therapeutics, Inc.-- -$0.74 $970.6M ARMPArmata Pharmaceuticals, Inc.68.08% -$0.74 $82.1M -
What do Analysts Say About DNLI or ARMP?
Denali Therapeutics, Inc. has a consensus price target of $32.00, signalling upside risk potential of 68.42%. On the other hand Armata Pharmaceuticals, Inc. has an analysts' consensus of $9.00 which suggests that it could grow by 50.25%. Given that Denali Therapeutics, Inc. has higher upside potential than Armata Pharmaceuticals, Inc., analysts believe Denali Therapeutics, Inc. is more attractive than Armata Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings DNLIDenali Therapeutics, Inc.17 0 0 ARMPArmata Pharmaceuticals, Inc.1 0 0 -
Is DNLI or ARMP More Risky?
Denali Therapeutics, Inc. has a beta of 1.115, which suggesting that the stock is 11.475% more volatile than S&P 500. In comparison Armata Pharmaceuticals, Inc. has a beta of 1.240, suggesting its more volatile than the S&P 500 by 23.97%.
-
Which is a Better Dividend Stock DNLI or ARMP?
Denali Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Armata Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Denali Therapeutics, Inc. pays -- of its earnings as a dividend. Armata Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios DNLI or ARMP?
Denali Therapeutics, Inc. quarterly revenues are --, which are smaller than Armata Pharmaceuticals, Inc. quarterly revenues of $1.2M. Denali Therapeutics, Inc.'s net income of -$126.9M is lower than Armata Pharmaceuticals, Inc.'s net income of -$26.7M. Notably, Denali Therapeutics, Inc.'s price-to-earnings ratio is -- while Armata Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Denali Therapeutics, Inc. is 6.62x versus 49.69x for Armata Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DNLIDenali Therapeutics, Inc.6.62x -- -- -$126.9M ARMPArmata Pharmaceuticals, Inc.49.69x -- $1.2M -$26.7M
-
Which has Higher Returns DNLI or NVAX?
Novavax, Inc. has a net margin of -- compared to Denali Therapeutics, Inc.'s net margin of -287.29%. Denali Therapeutics, Inc.'s return on equity of -44.34% beat Novavax, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital DNLIDenali Therapeutics, Inc.-- -$0.74 $970.6M NVAXNovavax, Inc.71.9% -$1.25 $94.5M -
What do Analysts Say About DNLI or NVAX?
Denali Therapeutics, Inc. has a consensus price target of $32.00, signalling upside risk potential of 68.42%. On the other hand Novavax, Inc. has an analysts' consensus of $12.67 which suggests that it could grow by 85.19%. Given that Novavax, Inc. has higher upside potential than Denali Therapeutics, Inc., analysts believe Novavax, Inc. is more attractive than Denali Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings DNLIDenali Therapeutics, Inc.17 0 0 NVAXNovavax, Inc.5 1 1 -
Is DNLI or NVAX More Risky?
Denali Therapeutics, Inc. has a beta of 1.115, which suggesting that the stock is 11.475% more volatile than S&P 500. In comparison Novavax, Inc. has a beta of 2.305, suggesting its more volatile than the S&P 500 by 130.478%.
-
Which is a Better Dividend Stock DNLI or NVAX?
Denali Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Novavax, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Denali Therapeutics, Inc. pays -- of its earnings as a dividend. Novavax, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios DNLI or NVAX?
Denali Therapeutics, Inc. quarterly revenues are --, which are smaller than Novavax, Inc. quarterly revenues of $70.4M. Denali Therapeutics, Inc.'s net income of -$126.9M is higher than Novavax, Inc.'s net income of -$202.4M. Notably, Denali Therapeutics, Inc.'s price-to-earnings ratio is -- while Novavax, Inc.'s PE ratio is 3.87x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Denali Therapeutics, Inc. is 6.62x versus 1.09x for Novavax, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DNLIDenali Therapeutics, Inc.6.62x -- -- -$126.9M NVAXNovavax, Inc.1.09x 3.87x $70.4M -$202.4M
-
Which has Higher Returns DNLI or PLX?
Protalix Biotherapeutics, Inc. has a net margin of -- compared to Denali Therapeutics, Inc.'s net margin of 13.19%. Denali Therapeutics, Inc.'s return on equity of -44.34% beat Protalix Biotherapeutics, Inc.'s return on equity of 12.06%.
Company Gross Margin Earnings Per Share Invested Capital DNLIDenali Therapeutics, Inc.-- -$0.74 $970.6M PLXProtalix Biotherapeutics, Inc.53.37% $0.03 $61.1M -
What do Analysts Say About DNLI or PLX?
Denali Therapeutics, Inc. has a consensus price target of $32.00, signalling upside risk potential of 68.42%. On the other hand Protalix Biotherapeutics, Inc. has an analysts' consensus of $11.00 which suggests that it could grow by 539.54%. Given that Protalix Biotherapeutics, Inc. has higher upside potential than Denali Therapeutics, Inc., analysts believe Protalix Biotherapeutics, Inc. is more attractive than Denali Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings DNLIDenali Therapeutics, Inc.17 0 0 PLXProtalix Biotherapeutics, Inc.1 0 0 -
Is DNLI or PLX More Risky?
Denali Therapeutics, Inc. has a beta of 1.115, which suggesting that the stock is 11.475% more volatile than S&P 500. In comparison Protalix Biotherapeutics, Inc. has a beta of -0.248, suggesting its less volatile than the S&P 500 by 124.798%.
-
Which is a Better Dividend Stock DNLI or PLX?
Denali Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protalix Biotherapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Denali Therapeutics, Inc. pays -- of its earnings as a dividend. Protalix Biotherapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios DNLI or PLX?
Denali Therapeutics, Inc. quarterly revenues are --, which are smaller than Protalix Biotherapeutics, Inc. quarterly revenues of $17.9M. Denali Therapeutics, Inc.'s net income of -$126.9M is lower than Protalix Biotherapeutics, Inc.'s net income of $2.4M. Notably, Denali Therapeutics, Inc.'s price-to-earnings ratio is -- while Protalix Biotherapeutics, Inc.'s PE ratio is 24.75x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Denali Therapeutics, Inc. is 6.62x versus 2.19x for Protalix Biotherapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DNLIDenali Therapeutics, Inc.6.62x -- -- -$126.9M PLXProtalix Biotherapeutics, Inc.2.19x 24.75x $17.9M $2.4M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
How High Could NVIDIA Stock Go?
NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…
Stock Ideas
Buy
51
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 61x
Buy
64
Is AAPL Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 38x
Buy
69
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Sell
47
PSTG alert for Dec 4
Pure Storage, Inc. [PSTG] is up 5.05% over the past day.
Sell
41
SMX alert for Dec 4
SMX (Security Matters) Plc [SMX] is up 154.74% over the past day.
Sell
43
HY alert for Dec 4
Hyster-Yale, Inc. [HY] is up 1.92% over the past day.
